Breaking News

Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact

Forge Biologics will provide process development and manufacturing services to support gene therapy for ultrarare disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Progeria Research Foundation (PRF), a research organization developing treatments for Hutchinson-Gilford Progeria Syndrome, and Forge Biologics, a manufacturer of gene therapies, entered a manufacturing agreement to support the development and manufacture of SamPro-2, PRF’s investigational gene therapy for adolescence with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. The manufacturing agreement leverages PRF’s research-driven Progeria program with Forge’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters